SELLAS Life Sciences Group Inc (NASDAQ:SLS) has a beta value of 2.23 and has seen 0.71 million shares traded in the recent trading session. The company, currently valued at $125.82M, closed the recent trade at $1.38 per share which meant it gained $0.07 on the day or 5.73% during that session. The SLS stock price is -33.33% off its 52-week high price of $1.84 and 44.2% above the 52-week low of $0.77. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.29 million shares traded. The 3-month trading volume is 2.46 million shares.
The consensus among analysts is that SELLAS Life Sciences Group Inc (SLS) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.11.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) trade information
Sporting 5.73% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SLS stock price touched $1.38 or saw a rise of 1.43%. Year-to-date, SELLAS Life Sciences Group Inc shares have moved 33.17%, while the 5-day performance has seen it change 22.57%. Over the past 30 days, the shares of SELLAS Life Sciences Group Inc (NASDAQ:SLS) have changed 14.46%. Short interest in the company has seen 8.18 million shares shorted with days to cover at 9.17.
Wall Street analysts have a consensus price target for the stock at $2.8, which means that the shares’ value could jump 50.71% from the levels at last check today.. The projected low price target is $2.4 while the price target rests at a high of $3.2. In that case, then, we find that the latest price level in today’s session is -131.88% off the targeted high while a plunge would see the stock gain -73.91% from the levels at last check today..
SELLAS Life Sciences Group Inc (SLS) estimates and forecasts
The company’s shares have gained 10.80% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 45.94% over the past 5 years. Earnings growth for 2025 is a modest 15.00% while over the next 5 years, the company’s earnings are expected to increase by 42.51%.
SLS Dividends
SELLAS Life Sciences Group Inc is expected to release its next earnings report on 2025-Mar-19 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
SELLAS Life Sciences Group Inc (NASDAQ:SLS)’s Major holders
Insiders own 0.13% of the company shares, while shares held by institutions stand at 6.82% with a share float percentage of 6.83%. Investors are also buoyed by the number of investors in a company, with SELLAS Life Sciences Group Inc having a total of 36.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 1.79 million shares worth more than $2.13 million. As of 2024-06-30, VANGUARD GROUP INC held 3.9862% of shares outstanding.
The other major institutional holder is SUSQUEHANNA INTERNATIONAL GROUP, LLP, with the holding of over 1.64 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.95 million and represent 3.6594% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 1.86% shares in the company for having 1.69 shares of worth $2.25 million while later fund manager owns 501.97 shares of worth $0.67 million as of Dec 31, 2024 , which makes it owner of about 0.55% of company’s outstanding stock.
